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ABSTRACT
The number of infections caused by microorganisms that are resistant to antibiotics and synthetic antibacterial drugs is growing 
fast worldwide. This is one of the most important and urgent problems in health care. The main efforts of researchers around the 
world are focused on solving this issue. Nitrofurans represent one of the most effective classes of antibacterial drugs. We have 
synthesized 4 analogues of nifuroxazide – a well known nitrofuran antibiotic – and confirmed their structures by NMR, IR spectros-
copy, and mass-spectrometry. All of the obtained compounds were studied for antimicrobial and antifungal activity.
Activity against Escherichia coli, Staphylococcus aureus, Staphylococcus haemolyticus, and Pseudomonas aeruginosa was evalu-
ated by the agar diffusion method. The synthesized compounds suppressed the growth of all the studied bacterial strains except 
Escherichia coli; the diameter of the inhibition zones ranged from 13.5 to 28 mm depending on the concentration of the tested 
compound and bacterial strain. One of the compounds studied in this project – the pyridine analogue of nifuroxazide – exceeded 
the activity of the standard (nifuroxazide) against the Staphylococcus aureus. The inhibitory activity of the synthesized compounds 
against the Candida albicans and Cryptococcus neoformans yeasts was determined using the microdilution method. The results were 
assessed according to the indicator color change. None of the studied compounds showed activity against these cultures.
The obtained results confirm that substituted nifuroxazides have significant antimicrobial activity and, therefore, can be con-
sidered as promising candidates for developing new antibacterial drugs.
INTRODUCTION
The increase in the number of microorganisms resis-
tant to antibiotics all over the world has become a seri-
ous problem for public health and veterinary medicine 
[1]. Patients infected with resistant strains have a higher 
mortality risk than patients with infections caused by 
non-resistant strains of the same microorganisms [2]. 
The modification of known antibiotics and the search for 
new antimicrobial synthetic drugs are the main direc-
tions of the modern pharmaceutical science [2, 3].
Over the course of the search for new synthetic an-
timicrobial drugs, significant attempts of scientists are 
focused on the discovery of new active nifuroxazide de-
rivatives. Therefore, Rollas et al. [4] provides an overview 
of a large number of structurally similar to nifuroxazide 
compounds with various substituents in the para- and 
ortho- positions of the benzene ring, most of which ex-
hibit high pharmacological activity comparable to mod-
ern fluoroquinolone drugs. Thota et al. [5] give examples 
of o-nitrofuran derivatives that are used as antibacte-
rial agents (Fig.  1). The authors conclude that acylhy-
drazones, which include substituted o-nitrofurans, are 
promising compounds for the development of new anti-
bacterial drugs.
Tavares et al. [6] described the synthesis and study 
of the antibacterial activity of nifuroxazide isosteres 
against Staphylococcus aureus (S.  aureus). According to 
Masunari et al. [7], new compounds of the nifuroxazide 
series have activity against the multi-resistant S. aureus. 
Some thiophene analogues of nifuroxazide exhibited 
higher antibacterial activity than nifuroxazide itself. Ni-
furoxazide and its analogues also showed significant ac-
tivity against the parasites Trypanosoma cruzi [8, 9] and 
Leishmania donovani [10]. According to Rando et al. [10], 
the thiophene analogues of nifuroxazide are significant-
ly more active against the Leishmania donovani parasite 
than the corresponding furan derivatives.
Nitrofurans are active against many gram-positive 
and gram-negative microorganisms as well as against 
some species of fungi and protozoa. Depending on the 
concentration, these substances have a bacteriostatic or 
bactericidal effect [11]. One of the main advantages of 
nitrofurans is the slow formation of bacterial resistance 
to this class of compounds [12].
Despite the fact that several nitrofuran compounds are 
used as drugs in various countries, the mechanism of ac-
tion of these compounds has not been studied in detail. It 
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is believed that the reduction of these substances by the 
appropriate enzymes in bacteria produces very active in-
termediates that destroy DNA, RNA, and other macromol-
ecules as well as lead to the disruption of a number of vital 
processes for bacteria, such as cell wall formation and pro-
tein synthesis [13]. A wide range of antimicrobial activity 
of these compounds is a possible reason for the absence of 
pronounced bacterial resistance to these drugs. 
In addition, the possibility of using substituted nitro-
furans as anti-cancer drugs has been widely discussed in 
recent publications; several publications are devoted to 
the study of the inhibitory effect of nifuroxazide on the 
growth of cancer cells and tumors [14-17].
The aim of this study was to search for effective syn-
thetic antimicrobial agents – substituted nitrofurans. 
Based on literature data analysis, it was decided to syn-
thesize several nifuroxazide isosteres, particularly com-
pounds containing a 4-dimethylaminophenyl fragment, 
and thiophene analogues of nifuroxazide, and to investi-
gate their antimicrobial activity. 
MATERIALS AND METHODS
Synthesis of nifuroxazide analogues 
Acylhydrazones were synthesized by the condensation of 
the corresponding hydrazides with aromatic nitroalde-
hydes using a modified procedure [10] (Fig. 4). The cor-
responding aromatic aldehyde was dissolved in ethanol 
with stirring and heating to 50℃. An equimolar amount 
of hydrazide was added in portions over 30 min and the 
reaction mixture was stirred for another 10 min. Reaction 
progress monitoring was accomplished using thin layer 
chromatography (TLC). After the reaction completion, 
the mixture was poured into cold water and the product 
was crystallized from water.
Confirmation of the structure and purity 
of the compounds
All the synthesized compounds were analyzed by NMR 
and IR spectroscopy and mass-spectrometry. The pu-
rity of all the synthesized compounds was determined 
using TLC and LC-MS (liquid chromatography – mass-
spectrometry) methods (Schimadzu Analytical HPLC 
LC10Avp, SPD-10A, autosampler Gilson 215, ELSD Sedex 
75 Mass analyzer PE SCIEX API 165, Japan). The NMR 
spectra (HTLab AG Avance III, Switzerland) and IR spectra 
(HTLab AG MPA, Switzerland) confirmed the structure of 
the obtained compounds, while the TLC and LC-MS data 
proved the high purity of all the reaction products. The 
spectral data as well as the results of TLC and LC-MS are 
presented below.
5-Nitro-2-furancarboxaldehyde p-dimethylamino-
benzoyl hydrazone (furan analogue) is a bright orange 
powder that is poorly soluble in ethanol and almost 
insoluble in water. Yield 91%. TLC (ethanol: hexane 
1: 5, Rf  =  0.6). 
1H NMR (400 MHz, DMSO-d6) δ (ppm): 
11.94 (s, 1H), 8.39 (s, 1H), 7.82 (d, J = 8.14 Hz, 2H), 7.79 
(d, J  =  4.42  Hz, 1H), 7.21 (d, J = 4.42 Hz, 1H), 6.77 (d, 
J = 8.14 Hz, 2H), 3.00 (s, 6H). IR (KBr) ν (cm-1): 3417 (NH), 
1529 (C = O), 1354 (NO2). LC-MS water/acetonitrile/tri-
fluoroacetic acid: 7.01 min. (m/z): 303.4 (M + 1).
3-Nitrobenzaldehyde p-dimethylaminobenzoyl 
 hydra zone (phenyl analogue) is a yellow powder that is 
soluble in hot ethanol and almost insoluble in water as 
well as poorly soluble in dioxane. Yield 92%. TLC (etha-
nol: hexane 1: 5, Rf = 0.4). 
1H NMR (300 MHz, DMSO-d6) 
δ (ppm): 11.60 (br s, 1H), 8.53 (s, 2H), 8.25 (d, J = 8.5 Hz, 
1H), 8.14 (d, J = 7.5 Hz, 1H), 7.83 (d, J = 8.2 Hz, 2H), 7.75 
(m, 1H), 6.75 (d, J = 8.2 Hz, 2H), 3.00 (s, 6H). 13C NMR 
(75.5 MHz, DMSO-d6) δ (ppm): 163.2, 153.6, 148.3, 143.5, 
136.7, 133.2, 130.4, 129.4, 123.9, 120.6, 119.1, 110.9, 39.6. 
IR (KBr) ν (cm-1): 3039 (CH), 1628 (C = O), 1352 (NO2). 
LC-MS: 7.32 min., (m/z): 313.3 (M + 1).
5-Nitro-2-thiophenecarboxaldehyde p-dimethyl-
amino benzoyl hydrazone (thiophene analogue) is a bright 
red crystalline powder that is soluble in hot ethanol and 
poorly soluble in water and hexane. Yield 87%. TLC (eth-
anol: hexane 1: 5, Rf = 0.5). 
1H NMR (400 MHz, DMSO-d6) 
δ (ppm): 11.90 (br s, 1H), 9.62 (s, 1H), 8.11 (d, J = 5.43 Hz, 
1H), 7.81 (d, J = 7.84 Hz, 2H), 7.51 (d, J = 5.43  Hz, 1H), 
6.26 (d, J = 7.84 Hz, 2H), 3.00 (s, 6H). 13C NMR (75.5 MHz, 
DMSO-d6) δ (ppm): 163.3, 152.7, 150.4, 147.5, 139.3, 
130.6, 129.5, 128.9, 118.7, 110.8, 39.58. IR (KBr) ν (cm-1): 
Fig. 1. Antimicrobial drugs – derivatives of o-nitrofuran [5].
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3052 (CH), 1342 (NO2), 603/682 (C - S). LC-MS: 7.37 min., 
(m/z): 319.3 (M + 1).
5-Nitro-2-thiophenecarboxaldehyde isonicotinoyl 
hydrazone (pyridine analogue) is a green-yellow pow-
der that is soluble in hot ethanol and poorly soluble in 
water and hexane. Yield 91%. TLC (ethanol: hexane 1: 5, 
Rf = 0.8). 
1H NMR (400 MHz, DMSO-d6) δ (ppm): 12.5 (s, 
1H), 8.8 (d, 2H), 8.7 (s, 1H), 8.3 (d, 1H), 7.8 (d, 2H), 7.6 (d, 
1H). IR (KBr) ν (cm-1): 3392 (NH), 1652 (C = N), 583/672 
(C - S). LC-MS: 5.72 min., (m/z): 277.3 (M + 1).
Bacteria and yeast
The activity of all the synthesized compounds was tested 
against the bacterial strains representing the most com-
mon causative agents of infectious diseases and nosoco-
mial infections [18]. All of the strains used in this study 
were obtained from the I. I. Mechnikov Research Institute 
for Vaccines and Sera (MRIVS) Collection – Escherichia 
coli (E. coli MRIVS 241), Staphylococcus aureus (S. aureus 
MRIVS 906), Staphylococcus haemolyticus (S.  haemolyti-
cus MRIVS 209), Pseudomonas aeruginosa (P. aeruginosa 
MRIVS 27853), Candida albicans (C. albicans MRIVS 927), 
and Cryptococcus neoformans (Cr.  neoformans MRIVS 
3465).
Evaluation of antimicrobial activity 
The method of diffusion into agar was used for the evalu-
ation of the antimicrobial activity of synthesized com-
pounds. Antimicrobial activity was determined by com-
paring the sizes of inhibition zones of bacterial growth 
according to the method described earlier [19, 20]. Since 
the tested compounds were only slightly soluble in water 
and poorly diffused into the agar, the concentration of 
the test solutions was increased to 2 mg/ml (as opposed 
to 1 mg/ml according to the method described in State 
Pharmacopoeia [19]). The test solutions were prepared as 
follows: 0.1 g of the tested compounds were dissolved in 
1.3 ml of 37% HCl, followed by the addition of 50 ml of 
distilled H2O and heating. Since all the compounds were 
basic and were protonated in an acidic medium, the pH of 
the final solutions was close to the physiological. A com-
mercial drug Enterofuryl (Bosnalijek, Bosnia and Herze-
govina) was used as a reference compound. Every capsule 
of this drug contains 200 mg of nifuroxazide. 
In order to determine the sensitivity threshold, the 
activities of solutions with sequential dilutions to 2, 4, 
and 8 times were estimated. The dilution of samples was 
performed with a normal saline solution.
Mueller-Hinton agar (MHA) was used for the assess-
ment of bacteria sensitivity following the procedure de-
scribed previously [21]. In order to prepare the inoculum, 
bacterial colonies were suspended in sterile isotonic so-
lution to a density of 0.5 according to McFarland turbidi-
ty standard. The inoculum was applied to the Petri dishes 
with the MHA and evenly distributed using a Drygalsky 
microbiological spatula. Wells with a diameter of 10 mm 
were made using the sterile punch followed by the addi-
tion of 100 μl of solutions of the investigated substances 
to the corresponding wells. Each Petri dish contained 
4 wells; the concentration in the first well was 2 mg/ml, 
while in the last one – 0.25 mg/ml for each of the 5 test-
ed substances. After the addition of samples to the agar 
containing bacteria, Petri dishes were incubated at 37℃ 
for 48 h. The antimicrobial activity of the corresponding 
compound was determined by measuring the diameters 
of the inhibition zones of bacterial growth.
The determination of antifungal activity of the syn-
thesized products against the strains C.  albicans and 
Cr.  neoformans was accomplished by the microdilution 
method performed in the round-bottom 96-well plate 
(Medpolymer, Russia) (Fig.  5) [22-24]. Both C.  albicans 
and Cr.  neoformans cultures were grown on a glucose-
peptone-yeast medium at 25℃ for 19  h. The 96-well 
plate was divided into 2 parts. The activity of compounds 
against C.  albicans was tested in the upper part while 
the activity against Cr. neoformans – in the lower part of 
the plate. Each part of the 96-well plate consisted of five 
rows of wells and each row was used to study the activ-
ity of one of the five synthesized compounds. The sixth 
row contained pure DMSO and served as a control. The 
solutions of tested compounds in dimethyl sulfoxide 
(DMSO) were added to the first well in a volume of 10 μl 
followed by twofold serial dilutions in sterile distilled 
water. DMSO was diluted in the same way. Then, 190 μl 
of the yeast suspension in a synthetic nutrient medium 
with a final cell concentration of 103 colony forming units 
(CFU/ml) containing pH indicator bromocresol blue (pH 
5.5, indicator color is blue) were added to each well. The 
final concentration of the compounds in the first well 
was 1024 μg/ml, and in the last one – 8 μg/ml. The syn-
thetic nutrient medium used in these experiments was 
prepared according to the method of Yarrow [25]. The 
mixing was carried out at the moment of addition of the 
larger volume of yeast suspension to the smaller volume 
of the tested compound. The incubation was carried out 
at 32℃. The activity of the studied compounds was es-
timated visually after 48 h of incubation. The change in 
the color of the indicator from blue to yellow reveals the 
pH change of the medium, which indicates the growth of 
the yeast culture and the absence of activity of the tested 
compounds.
Statistical data processing
The antimicrobial and antifungal activity tests were 
performed 3  times for each studied compound and the 
average activity values  were calculated. All of the data 
were subjected to statistical analysis. The results were 
processed using standard Microsoft Excel software for 
Windows. Data were presented as mean (M) ± standard 
deviation (SD).
RESULTS
Synthesis and analysis of the chemical compounds 
We assumed that it is possible to obtain a more effective 
analogue of an existing drug nifuroxazide by the directed 
modification of its structure while preserving the phar-
macophore.
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After analysis of the structures of active nitrofurans, 
a pharmacologically significant fragment (pharmaco-
phore) – 2-iminomethyl-5-nitrofuran – was selected 
(Fig. 2).
Fig. 2. Structure of pharmacophore (2-iminomethyl-5-nitrofuran).
The basic assumption was that any active analogue of 
nifuroxazide should have a nitro group in the fifth posi-
tion and an iminomethyl group in the second position of 
the furan ring. This approach gives broad possibilities for 
the structural design of drug candidates among the aro-
matic and heterocyclic compounds. The structures of the 
studied drug candidates are shown in Fig. 3.
The synthesis of the nifuroxazide derivatives is shown 
in Fig. 4. Reactions were carried out in ethanol at boiling.
The structure of all obtained compounds was con-
firmed by NMR and IR spectroscopy, and the TLC and 
LC-MS data showed their high purity. The analytical 
data are presented in the Materials and Methods sec-
tion.
Inhibitory activity of compounds against bacteria 
and yeast
The sizes of zones of bacterial growth inhibition are 
shown in Table  1. The commercial drug Enterofuryl 
served as a positive control. The measurement of bac-
terial growth inhibition zones showed that the con-
trol drug Enterofuryl inhibited the growth of S. aureus, 
S.  haemolyticus, and P.  aeruginos at a concentration of 
2.0 mg/ml and did not suppress the growth of these mi-
croorganisms at lower concentrations (1.0  mg/ml and 
0.5 mg/ml). In all of the studied concentrations, Entero-
furyl did not inhibit the growth of E.  coli. The lack of 
Enterofuryl activity against the non-enteropathogenic 
E. coli MRIVS 241 strain used in our study does not ex-
clude the sensitivity of other E.  coli strains, including 
pathogenic strains, to this drug. Similar results were ob-
tained for analogues 1, 2, and 3. Unlike Enterofuryl and 
analogues 1, 2, and 3, the pyridine analogue (analogue 4) 
inhibited the growth of S. aureus not only at a concentra-
tion of 2.0 mg/ml but also at concentrations of 1.0 mg/ml 
and 0.5  mg/ml. The inhibitory activity of analogue 4 
against P. aeruginosa, S. haemolyticus, and E. coli did not 
differ from that of other compounds.
The results of the study of the inhibitory activity 
of the synthesized compounds against C.  albicans and 
Cr. neoformans are shown in Fig. 5. The color change of 
the indicator from blue to yellow in the course of 48 h 
incubation in the control wells with the DMSO solution 
as well as in all of the wells with the tested compounds 
indicated the acidification of the medium by the prod-
ucts of yeast metabolism, i.e. their unimpeded growth. 
Consequently, none of the studied samples or the con-
trol drug Enterofuryl were active against C. albicans and 
Cr. neoformans in the studied concentration range.
DISCUSSION
The antimicrobial activity of four synthesized nifuroxa-
zide analogues was studied against the strains of S. au-
reus, S. haemolyticus, P. aeruginosa, and E. coli as well as 
against the clinically significant yeast species C. albicans 
and Cr. neoformans. The experiments conducted in this 
study showed that all of the tested compounds were 
Table 1. The diameter of the growth inhibition zones of the bacterial test-cultures for the studied compounds
Nifuroxazide derivatives, concentration used 
(mg/ml)
Diameter of the growth inhibition zones of test cultures (mm)
S. aureus S. haemolyticus P. aeruginosa E. coli.
1. Phenyl analogue (analogue 1)
2 mg/ml 15.5±0.5 17.5±0.5 14.0±0.5 0
1 mg/ml 0 0 0 0
0.5 mg/ml 0 0 0 0
2. Thiophene analogue (analogue 2)
2 mg/ml 15.3±0.6 20.0±0 18.3±0.3 0
1 mg/ml 0 0 0 0
0.5 mg/ml 0 0 0 0
3. Furan analogue (analogue 3)
2 mg/ml 18.5±0.5 22.3±0 16.0±0 0
1 mg/ml 0 0 0 0
0.5 mg/ml 0 0 0 0
4. Pyridine analogue (analogue 4)
2 mg/ml 25.3±0.6 27.8±0.3 18.0±0 0
1 mg/ml 18.3±0.3 0 0 0
0.5 mg/ml 16±0 0 0 0
5. Enterofuryl
2 mg/ml 19.7±0.3 21.2±0.3 21.5±0.5 0
1 mg/ml 0 0 0 0
0.5 mg/ml 0 0 0 0
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Fig. 3. Chemical structures of the studied compounds. A – phenyl analogue (analogue 1), heterocyclic analogues: B – thiophene analogue 
(analogue 2), C – furan analogue (analogue 3), D – pyridine analogue (analogue 4).
Fig. 4. Schemes for the synthesis of nifuroxazide derivatives. A – synthesis of the phenyl analogue (analogue 1), B – synthesis of the thio-
phene and furan analogues (analogues 2 and 3), C – synthesis of the pyridine analogue (analogue 4).
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active against S.  aureus, S.  haemolyticus, and P.  aerugi-
nosa strains at a concentration of 2 mg/ml while only the 
pyridine analogue (analogue 4) inhibited the growth of 
the S. aureus strain at lower concentrations of 1 mg/ml 
and 0.5 mg/ml. None of the studied compounds had an 
inhibitory effect on the E.  coli strain. In addition, none 
of the tested compounds were active against the yeast 
C. albicans and Cr. neoformans in the studied concentra-
tion range.
Analysis of the antibacterial activity data of the stud-
ied compounds allows us to conclude that the replace-
ment of the five-membered heteroaromatic ring with a 
six-membered phenyl ring led to a significant decrease 
in antimicrobial activity, while all of the furan and thio-
phene analogues inhibited the growth of microorgan-
isms at a rate close to the standard (nifuroxazide). This 
result probably indicates the fundamental importance 
of the presence of the five-membered electron rich aro-
matic fragment in the structure of these compounds. The 
transition from the furan ring to the thiophene in the 
presence of a bulky substituent (dimethylamino group) 
had little effect on antimicrobial activity, while the fu-
ran and thiophene analogues showed a small difference 
in inhibitory activity against the growth of microorgan-
isms compared to the standard (nifuroxazide). The most 
promising compound appeared to be compound 4 – the 
pyridine analogue of nifuroxazide. The combination of a 
thiophene ring and pyridine fragment with the absence 
of a large substituent in the side chain in this compound 
led to the highest antimicrobial activity compared to all 
of the tested compounds. This substance showed a higher 
inhibition rate against S. aureus strain than the standard 
(nifuroxazide).
Over the course of the study of antibacterial activity 
of a number of heterocyclic molecules that belong to the 
same class of compounds, it is usually possible to find a 
correlation between the molecular structure and the dis-
tribution of the electron density in the molecule and its 
antimicrobial activity. In the case of nifuroxazide deriva-
tives, the analysis of literature data and our results did 
not allow us to draw concrete conclusions in this regard.
According to the modern concept about the mecha-
nism of action of nifuroxazide and its analogues, the 
active form of the drug is produced by the reduction 
of the drug molecule by the corresponding enzymes in 
bacteria [13]. Therefore, it is logical to assume that the 
activity of nifuroxazide analogues depends upon their 
redox potential and, accordingly, upon the presence of 
electron-donor or electron-acceptor substituents in the 
molecule. Indeed, according to Masunari and Tavares 
[7], the introduction of electron-acceptor substituents 
in the para-position of the phenyl ring of the thiophene 
analogues of nifuroxazide leads to the increased activ-
ity of these drugs against S. aureus, while the introduc-
tion of electron-donor substituents, respectively, de-
creases the activity of these analogues. However, this 
contradicts the data of Rando et al. [26], who studied 
the effect of these compounds on Mycobacterium tuber-
culosis and showed that analogues with donor substitu-
ents are significantly more active than the correspond-
ing halogen-containing analogue against this bacterial 
strain. This assumption is also not supported by the re-
sults obtained by Popiolek and Biernasiuk [27] and Zorzi 
et al. [28], who studied the activity of furan analogues 
of nifuroxazide. According to their data, the biological 
activity of these compounds against S. aureus does not 
depend on the introduction of electron-donor or elec-
tron-acceptor substituents in the para-position of phe-
nyl ring. The lack of this correlation was also confirmed 
by the results of Paula et al. [29], who determined the 
Fig. 5. The growth of the yeast C. albicans MRIVS 927 and Cr. neoformans MRIVS 3465 in the presence of the studied compounds: A – 0 h of 
incubation, B – 48 h of incubation. In the first well of every row on the 96-well plate the concentration of compounds is equal to 1024 μg/ml 
and then the concentration decreases with a step of 2 to 8 μg/ml in the last well. The numbers denote the compounds: 1 – thiophene ana-
logue (analogue 2), 2 – furan analogue (analogue 3), 3 – pyridine analogue (analogue 4), 4 – phenyl analogue (analogue 1), 5 – Enterofuryl. 
K – negative control (wells 1 and 2) containing pure DMSO.
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redox potentials of furan and thiophene analogues of 
nifuroxazide. The authors concluded that the introduc-
tion of various substituents into the molecule has very 
little effect on its redox potential, and that the redox 
potentials of the substituted furan and thiophene nifu-
roxazide analogues have a very small difference. These 
findings may explain the opposite results obtained in 
the studies of Tavares et al. [30] and Alsaeedi et al. [31] 
who compared the activity of the substituted furan and 
thiophene analogues against the different strains of 
bacteria.
The activity tests of all the synthesized compounds 
against the clinically significant strains of yeast C. al-
bicans MRIVS 927 and Cr.  neoformans MRIVS 3465 
showed that all of the four synthesized nifuroxazide 
analogues and the standard – Enterofuryl – did not in-
hibit the growth of these yeast strains in the studied 
range of concentrations. This result corresponds to the 
literature data. Therefore, Popiolek and Biernasiuk [27] 
showed that the replacement of the hydroxy group in 
the nifuroxazide molecule with substituents, such as 
halogen, methoxy group, amino group, or dimethyl-
amino group, did not lead to the emergence of activity 
against C. albicans ATTC 10231. The only aromatic ana-
logue of nifuroxazide the authors described with a very 
weak activity against this yeast contained a fragment 
of nicotinic acid hydrazide. Only half of the twenty-two 
aromatic analogues of nifuroxazide, studied by Zorzi et 
al. [28], showed very weak activity against C.  albicans 
ATCC 537Y.
Since it is impossible to find a correlation between the 
structure of the molecule and its antimicrobial activity 
based on our current knowledge, the search for new ac-
tive drug candidates among nifuroxazide analogues is no 
trivial task. The discovery of a new active compound as a 
result of our study – the pyridine analogue of nifuroxa-
zide – is of considerable interest for the development of 
new heterocyclic antimicrobial drug candidates in the 
series of furan and thiophene derivatives.
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